O ver the past 20 years, there has been considerable interest in the elucidation of factors that mediate angiogenesis. Early efforts, including Michaelson's description of "Factor X" in mediating retinal neovascularization and Folkman's attempts at isolating "tumor angiogenesis factor," have blossomed into a plethora of investigations identifying regulators, both positive and negative, of blood vessel formation. 1, 2 These efforts led to the identification of factors such as vascular endothelial growth factor, acid-and basic-fibroblast growth factor, angiogenin, and angiopoietins, to name a few. [3] [4] [5] Subsequent detailed investigations have revealed that finely tuned and precisely coordinated expression of these factors is critical for angiogenesis during both development and adult life. Failure to coordinate expression has significant implications, as excess angiogenesis can contribute to tumor growth and inflammatory disorders, whereas insufficient angiogenesis can contribute to ischemic heart disease and preeclampsia. 6
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More recently, additional angiogenic mediators, including Notch, Wnt, and morphogens such as bone morphogenetic proteins (BMPs), have emerged as critical regulators for proper blood vessel formation. BMPs, members of the transforming growth factor-␤ superfamily of proteins, were initially characterized by their ability to induce ectopic bone and cartilage formation. 7 Importantly, gain-and loss-of-function studies reveal that BMPs, notably BMP2 and BMP4, are proangiogenic factors. 8 BMP action can be regulated at multiple levels, including through reversible interactions with endogenous extracellular antagonists. 9 In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Moreno-Miralles et al provide the inaugural in vivo functional evidence that 1 of these endogenous BMP regulators, termed BMP-binding endothelial cell precursor-derived regulator (BMPER), alters BMP signaling and angiogenesis in response to physiological stimuli. 10 Originally characterized through efforts to identify genes involved in early endothelial cell differentiation during vasculogenesis by the Patterson laboratory, BMPER has been ascribed both pro-and anti-BMP signaling properties in the context of angiogenesis. Moreover, recent reports suggest that the ratio of BMPER:BMP expression is critical in conveying this biphasic effect. [11] [12] [13] using in vivo loss-offunction approaches, Moreno-Miralles et al now demonstrate an in vivo mechanism by which BMPER acts as an endogenous antagonist to BMP signaling. 10 Based on previous findings that BMPER regulates BMP4-dependent angiogenesis, 14 Moreno-Miralles et al demonstrate that the expression of Bmper but not that of Bmp4 is negatively regulated in response to hypoxia, both in vitro and in vivo. Furthermore, BMP signaling, as measured by phosphorylated Smad 1/5/8, is potentiated. Given that hypoxia is both a negative regulator of Bmper expression and a potent angiogenic stimulus, one would anticipate that loss of Bmper expression in vivo may potentiate the hypoxia-induced angiogenic response. Because BmperϪ/Ϫ mice are embryonic lethal, 15 efforts to address this question used Bmperϩ/Ϫ mice. Although these animals exhibit normal retinal vascular area and scaffolding at baseline, when subjected to hypoxic challenge, they display increased rates of revascularization along with enhanced BMP activity (as evidenced by SMAD phosphorylation). In an attempt to elucidate the temporal resolution and potential mechanism involving the increased rate of revascularization in Bmperϩ/Ϫ mice, Moreno-Miralles et al provide evidence that Bmper expression is reduced and SMAD activity is potentiated more rapidly in response to hypoxia in haploinsufficient mice compared with wild-type controls. Importantly, in the context of hypoxia, this correlates with a more rapid induction of downstream target genes (Mmp9 and Msx1) in Bmperϩ/Ϫ mice. Taken together, these findings support and extend previous models 14, 15 suggesting that (1) endogenous BMPER is an anti-BMP signaling modulator and (2) the ratio of BMPER to BMP is critical in determining the in vivo angiogenic response to a physiological stimulus (Figure) .
The importance of the BMPER:BMP ratio provided in the current work 10 builds on previous observations by the Blair/ O'Connor and Patterson laboratories. The former group demonstrated that activity of crossvienless-2, the Drosophila ortholog of BMPER, is biphasic, with low levels of crossvienless-2 promoting BMP signaling during Drosophila wing development and high levels inhibiting it. 16 The Patterson laboratory corroborated these results in vertebrates by showing that BMPER binds BMP4 with a 2:1 molar stoichiometry and that, when this molar ratio is exceeded, BMPER restricts BMP4 signaling and initiates BMP endocytosis and lysosome degradation. 15 The authors proposed an endocytic trap and sink mechanism whereby the N terminus of BMPER traps extracellular BMP4 and prevents SMAD activation, whereas the BMPER C terminus is required to sink BMP4 into the cell for more efficient BMP4 degradation and inhibition of signaling. Interestingly, concentration depen- dence has also been reported for other endogenous antagonists that regulate BMP signaling, including noggin and chordin. 17 Collectively, these studies highlight the importance of the relative concentration of both positive and negative regulators in facilitating angiogenesis. In addition to angiogenesis, the current work may also have implications for other vascular pathologies. For example, altered BMP signaling has been associated with genetic vascular disorders such as hemorrhagic hereditary telangiectasia. 18 Furthermore, BMP signaling has also been implicated in the development of pulmonary artery hypertension and preeclampsia. 18 Consequently, manipulating the BMP signaling axis-perhaps through BMPER-offers an opportunity for therapeutic gain. Such efforts would be facilitated by a better understanding of how BMPER expression is regulated or a detailed understanding of the structural basis for its interaction with BMPs. In this regard, recent studies have identified KLF and FOXO factors as upstream regulators of BMPER expression. 19, 20 Moreover, insights gained from structure-function studies 15 will likely provide the foundation for the development of small molecules or novel compounds to manipulate the BMP-BMPER interaction and alter vascular disease states.
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